USPTO serial 79287183
EPITOX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 6, 2021
- Examiner
- LEE, JANET H
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with EPITOX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $325
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Benjamin M. Cantor
Benjamin M. Cantor Cantor Colburn LLP20 Church Street22nd FloorHartford, CT 06103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for treating middle of the forehead wrinkles, facial wrinkles, asymmetries and defects and conditions of the human skin; pharmaceutical preparations for treating orthopaedic purposes; pharmaceutical preparations acting on the central nervous system; analgesic preparations; medicines for dental purposes; therapeutic drugs and agents as pharmaceuticals for treatment of wrinkles; pharmaceutical preparations for treating pain; pharmaceutical products for skin care for medical purposes, namely, botulinum toxin, botulinum toxin-hemagglutinin complex, botulinum toxin fragments and other derivatives; pharmaceutical preparations for treating neurological diseases, namely, botulinum toxin, botulinum toxin-hemagglutinin complex, botulinum toxin fragments and other derivatives; pharmaceutical preparation for skin care; medicated skin preparation for use in treating wrinkles; pharmaceutical preparations for treatment of respiratory organ disorder; preparations for the treatment of burns; preparations for the treatment of scar; pharmaceutical agents affecting sensory organs; pharmaceutical preparations for treating muscle disorders; pharmaceutical agents affecting metabolism; bacterial poisons; anaesthetics; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for treating middle of the forehead wrinkles; pharmaceutical preparations for use in the cosmetic field, namely, medicated cosmetics; pharmaceuticals containing botulinum toxin for medical use for use in the treatment of neurological disorders, muscle disorders, nerve disorders, headaches, wrinkles, sports injuries, spasms, tremors and pain; botulinum toxin for medical use for use in the treatment of neurological disorders, muscle disorders, nerve disorders, headaches, wrinkles, sports injuries, spasms, tremors and pain; pharmaceutical preparations for the treatment of urogenital organ disorders; pharmaceutical preparations for plastic surgery; anti-inflammatory and antipyretic preparations; pharmaceutical agents affecting digestive organs; veterinary substances and preparations for house pets for injuries and pain, namely, pharmaceuticals containing botulinum toxin; cardiovascular agents for medical purposes; pharmaceutical preparations for treating neurological disorders; ophthalmic preparations; pharmaceutical preparations for treating facial cramps; allergy medications; chemical preparations for pharmaceutical purposes, namely, for neurological disorders, muscle disorders, nerve disorders, headaches, wrinkles, sports injuries, spasms, tremors and pain; chemico-pharmaceutical preparations, namely, for neurological disorders, muscle disorders, nerve disorders, headaches, wrinkles, sports injuries, spasms, tremors and pain; pharmaceutical preparations for treating facial wrinkles; pharmaceutical agents for epidermis; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of neurological disorders, muscle disorders, nerve disorders, headaches, wrinkles, sports injuries, spasms, tremors and pain; medicines for human purposes, namely, pharmaceutical preparations for the treatment of neurological disorders, muscle disorders, nerve disorders, headaches, wrinkles, sports injuries, spasms, tremors and pain | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 6, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 6, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 28, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 4, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 4, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 6, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 6, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 20, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 20, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 18, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 31, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 31, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 31, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 18, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 18, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 18, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 18, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 18, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 25, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 24, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 24, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 5, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 2, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 27, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 5, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 24, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 17, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 16, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 15, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 16, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 12, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 11, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |